Subscribe to Search results

The individual patient data shows people being treated with NHS and commercial concentrate and with more than one type of commercial concentrate.

Published on:

In December 1984, Oxford Haemophilia Centre placed its first order for heat-treated concentrates

Published on:

In Bradford, in 1982, there was a move away from the use of cryoprecipitate to factor concentrates and the introduction of home treatment

Published on:

In Bradford, in 1983, no cryoprecipitate was used for the treatment of patients with Haemophilia A; all treatment was with concentrates (NHS, Factorate and Kryobulin)

Published on:

In a Blood Transfusion Services meeting on 4th December 1984 it was said, theoretically, "heat-treated material was likely to be safer than non-treated material"

Published on:

Local directors in Bradford, having discussed the Elstree protocols, did not want interim heat-treated product that would only likely be available two or three months and preferred to wait until April when "a better product is promised"

Published on:

In 1976, St George's Hospital had begun to shift away from cryoprecipitate and towards concentrate, predominantly commercial. Predominantly still cryoprecipitate used.

Published on:

In 1983, an annual return for St George's Hospital showed a significant shift to commercial concentrate (Armour) for both hospital and home treatment, with very little cryoprecipitate and some NHS concentrate

Published on:

The annual return for Guy's for 1982 shows that 229,675 units of concentrate were used in the treatment of 21 patients with Haemophilia A

Published on:

The annual return reported 160,575 units of concentrate were used in the treatment of 17 patients with Haemophilia .

Published on:

Cryoprecipitate was used for the treatment of Haemophilia A to an extent, but most treatment was with NHS concentrate.

Published on:

When Dr Winter sent sera to Dr Tedder for testing in October 1984, all but one was positive for HIV. About half of those were children and some were people with moderate haemophilia.

Published on:

Dr Winter recalled Professor Bloom saying "You are mad to switch. There will never be HIV in BPL Factor VIII."

Published on:

Dr Mark Winter described it as "utterly bizarre" for doctors to discuss not providing results unless the patient asks for it.

Published on:

Dr Colvin did use substantial quantities of NHS Factor 8 (1,100,392 units) as well as 148,540 units of cryoprecipitate and 388,654 units of commercial concentrate (Koate,
Factorate, Hemofil and Kryobulin) for the treatment of 78 patients with Haemophilia A.

Published on:

It appeared that substantial quantities of NHS Factor 8, cryoprecipitate and commercial concentrate were used for the treatment of patients.

Published on:

A reduction in the purchase of commercial concentrate in 1983 was due to an increase in supply of NHS material demonstrating Dr Colvin's intent to minimise risk where and when it was sensible to do so.

Published on:

In reference to the risks of AIDS in haemophilia services, possible complications in treatment were described as "Plasma product-transmitted disease, particularly hepatitis and (possibly) the acquired immune deficiency syndrome (AIDS)"

Published on:

Dr Colvin wrote that they knew little about AIDS at this time. The health service should not "spurn" commercial concentrate as they must stay aware of the risks associated with NHS material.

Published on:

It was stated that "until a positive test for AIDS and/or a vaccine is developed it should be policy to avoid use of blood products except for essential treatments and to use cryoprecipitate or plasma instead of FVIII Concentrate whenever possible."

Published on: